Association analysis between genomic variants within advanced glycation end product specific receptor (AGER) gene and risk of breast cancer in Iranian women. Issue 10 (October 2019)

• Record Type: Journal Article
• Authors: Ghafouri-Fard, Soudeh; Noroozi, Rezvan; Musavi, Mehrnoosh; Taheri, Mohammad
• Is Part Of: Heliyon. Volume 5:Issue 10(2019)
• Publication Date: 2019-10
• Subjects: Epidemiology -- Genetics -- Cancer research -- Bioinformatics -- Oncology -- AGER -- Advanced glycation end-product -- Breast cancer; Research -- Periodicals; Medical sciences -- Periodicals; Natural history -- Periodicals; Social sciences -- Periodicals; Earth sciences -- Periodicals; Physical sciences -- Periodicals; 507.2
• DOI: 10.1016/j.heliyon.2019.e02542
• Languages: English
• ISSNs: 2405-8440

Abstract

Abstract: The advanced glycation end product specific receptor ( AGER ) gene codes for a cell surface receptor which is one of the immunoglobulin superfamily members. This gene has a number of single nucleotide polymorphisms (SNPs) whose variants are associated with altered function of the encoded protein. In the current project, we examined association between rs184003 and rs1800625 SNPs and susceptibility to breast cancer in an Iranian population. The current study excludes participation of rs184003 AGER variant in conferring cancer risk. However, for the rs1800625, based on the calculated P value, the results should be assessed in larger cohorts. Primarily, the rs1800625 SNP was associated with breast cancer risk in dominant model (OR (95% CI) = 1.79 (1.03–3.11)), but after correction for multiple comparisons it did not reach the level of significance (adjusted P value = 0.07). The other SNP was not associated with breast cancer risk in any inheritance model. Haplotype analyses revealed a trend toward association between the GC haplotype (rs184003 and rs1800625 respectively) and risk of breast cancer (OR (95% CI) = 1.77 (1.09–2.88), adjusted P value = 0.08)). The current study excludes participation of rs184003 AGER variants in conferring cancer risk. However, for the rs1800625, based on the calculated P value, the results should be assessed in larger cohorts.